• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Executive Officer Hunt Anthony bought $248,160 worth of shares (2,000 units at $124.08), increasing direct ownership by 1% to 165,177 units (SEC Form 4)

    6/14/24 5:41:04 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGEN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hunt Anthony

    (Last) (First) (Middle)
    C/O REPLIGEN CORPORATION
    41 SEYON ST., BLDG 1, STE 100

    (Street)
    WALTHAM MA 02453

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    REPLIGEN CORP [ RGEN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    06/14/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/14/2024 P 2,000 A $124.08 165,177 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Kimberly Brown (Attorney in Fact) 06/14/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RGEN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RGEN

    DatePrice TargetRatingAnalyst
    7/22/2025$160.00Overweight
    Stephens
    6/24/2025$150.00Overweight
    Barclays
    4/29/2025$160.00Peer Perform → Outperform
    Wolfe Research
    3/18/2025$155.00In-line
    Evercore ISI
    2/10/2025$200.00Buy
    TD Cowen
    12/17/2024$165.00Hold
    Canaccord Genuity
    11/14/2024Peer Perform
    Wolfe Research
    8/28/2024$180.00Overweight
    Wells Fargo
    More analyst ratings

    $RGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens resumed coverage on Repligen with a new price target

    Stephens resumed coverage of Repligen with a rating of Overweight and set a new price target of $160.00

    7/22/25 7:54:12 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on Repligen with a new price target

    Barclays initiated coverage of Repligen with a rating of Overweight and set a new price target of $150.00

    6/24/25 8:09:38 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Repligen from Peer Perform to Outperform and set a new price target of $160.00

    4/29/25 2:20:14 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Madaus Martin D bought $201,830 worth of shares (1,800 units at $112.13) (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    8/12/25 12:47:07 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Barthelemy Nicolas was granted 973 shares, increasing direct ownership by 28% to 4,441 units (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    5/21/25 3:00:13 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Konstantinov Konstantin was granted 973 shares, increasing direct ownership by 51% to 2,894 units (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    5/19/25 8:26:29 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

    WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign's machine learning and modeling workflow into Repligen filtration systems. As part of the partnership, Repligen will invest in Novasign to help scale and expand operations. Through this collaboration, Novasign's unique modeling workflow will be integrated into Repligen's tangential flow filtration (TFF) systems. This will not only enhance Repligen's digitalization journey and strengthen its portfolio of process analyt

    7/31/25 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

    Revenue of $182 million, year-over-year increase of 15% as reported and 17% organic non-COVID growthOrders grew sequentially and greater than 20% year-over-yearIncreasing revenue guidance to range of $715 to $735 million, which represents 12.5% -15.5% year-over-year non-COVID organic growth WALTHAM, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2025, covering the three- and six- month periods ended June 30, 2025. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2025 an

    7/29/25 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen to Report Second Quarter 2025 Financial Results

    WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2025 financial results on Tuesday, July 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six- month reporting periods ended June 30, 2025. The conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the

    7/17/25 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Madaus Martin D bought $201,830 worth of shares (1,800 units at $112.13) (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    8/12/25 12:47:07 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Pax Margaret bought $37,672 worth of shares (250 units at $150.69), increasing direct ownership by 32% to 1,043 units (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    3/18/25 3:58:05 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Madaus Martin D bought $201,776 worth of shares (1,615 units at $124.94) (SEC Form 4)

    4 - REPLIGEN CORP (0000730272) (Issuer)

    6/14/24 6:07:59 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    SEC Filings

    View All

    SEC Form 10-Q filed by Repligen Corporation

    10-Q - REPLIGEN CORP (0000730272) (Filer)

    8/7/25 4:46:31 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REPLIGEN CORP (0000730272) (Filer)

    7/29/25 7:31:44 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - REPLIGEN CORP (0000730272) (Filer)

    5/15/25 4:15:37 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Financials

    Live finance-specific insights

    View All

    Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

    Revenue of $182 million, year-over-year increase of 15% as reported and 17% organic non-COVID growthOrders grew sequentially and greater than 20% year-over-yearIncreasing revenue guidance to range of $715 to $735 million, which represents 12.5% -15.5% year-over-year non-COVID organic growth WALTHAM, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2025, covering the three- and six- month periods ended June 30, 2025. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2025 an

    7/29/25 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen to Report Second Quarter 2025 Financial Results

    WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2025 financial results on Tuesday, July 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six- month reporting periods ended June 30, 2025. The conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the

    7/17/25 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Repligen Reports First Quarter 2025 Financial Results

    Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growthOrders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic revenue guidance of 9.5% - 13.5% WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025. Olivier Loeillot, President and Chief Executive Officer

    4/29/25 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGEN
    Leadership Updates

    Live Leadership Updates

    View All

    908 Devices Appoints Christopher D. Brown to its Board of Directors

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

    6/16/25 8:00:00 AM ET
    $AAPL
    $MASS
    $RGEN
    Computer Manufacturing
    Technology
    Industrial Machinery/Components
    Industrials

    Repligen Appoints Jacob Johnson As Vice President Investor Relations

    WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team's engagement with the investment community, reporting to the company's Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector. Mr. Garland commented, "Jacob is a terrific addition to the Repligen team, bringing a broad understanding of the bioprocessing tools space, the markets we serve and the growth driver

    4/8/25 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

    BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is

    12/16/24 8:11:00 AM ET
    $BLFS
    $RGEN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $RGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Repligen Corporation

    SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

    11/14/24 1:22:37 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Repligen Corporation

    SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

    9/10/24 5:08:30 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Repligen Corporation (Amendment)

    SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

    2/14/24 10:02:59 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care